Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
244 hedge funds and large institutions have $5.2B invested in Apellis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 96 increasing their positions, 83 reducing their positions, and 40 closing their positions.
46% more call options, than puts
Call options by funds: $81.6M | Put options by funds: $55.8M
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
16% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 83
2.12% more ownership
Funds ownership: 88.77% → 90.89% (+2.1%)
2% less funds holding
Funds holding: 250 → 244 (-6)
10% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 40
22% less capital invested
Capital invested by funds: $6.65B → $5.2B (-$1.45B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$210M |
| 2 |
JP Morgan Chase
New York
|
+$48.1M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$36.6M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$34.8M |
| 5 |
BlackRock
New York
|
+$32.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$63.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$63.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$57.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$31.9M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$29.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
V
276
Veritable
Wilmington,
Delaware
| – | -$242K | -3,543 | Closed |
|
|
AIM
277
Aigen Investment Management
New York
| – | -$235K | -3,438 | Closed |
|
278
Franklin Resources
San Mateo,
California
| – | -$228K | -3,337 | Closed |
|
|
GT
279
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$215K | -3,157 | Closed |
|
|
CAM
280
Cresset Asset Management
Chicago,
Illinois
| – | -$205K | -3,000 | Closed |
|
|
CMP
281
Coston McIsaac & Partners
Bar Harbor,
Maine
| – | -$136K | -2,000 | Closed |
|
|
PHK
282
Point72 Hong Kong
Hong Kong
| – | -$65K | -950 | Closed |
|
|
DFCM
283
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$35K | -519 | Closed |
|
|
CAL
284
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | -$159 | -3 | -27% |
|
APLS Hedge Fund Activity: Q4 2022 in Review
244 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2022, worth a combined $5.2B — down 22% from $6.65B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of APLS and 36 opened new positions — a net loss of 4 holders — while 83 trimmed existing stakes and 96 added.
The largest buyer was Janus Henderson Group, adding an estimated $210M. The largest seller was Viking Global Investors, exiting entirely with an estimated $63.7M sold.
- 244 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2022, down from 250 in Q3 2022.
- Funds reported $5.2B of Apellis Pharmaceuticals stock for Q4 2022, down 22% quarter-over-quarter.
- 36 funds opened new Apellis Pharmaceuticals positions in Q4 2022 and 40 closed out, a net change of -4 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2022 was Janus Henderson Group, an estimated $210M added.
- The largest Apellis Pharmaceuticals seller in Q4 2022 was Viking Global Investors, an estimated $63.7M sold.
Based on aggregated 13F filings for Q4 2022.